Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar

31

Featured Webinar

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.

Apr

06

Featured Webinar

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.

Menu

BTIG Initiates Coverage of Fulgent Genetics

To read the full story....

Breaking News

FDA Issues EUA to Adaptive Biotechnologies Test for T-Cell Response to COVID-19

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

German Stores to Begin Selling COVID-19 Rapid Antigen Tests for Home Use

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

DermTech Q4 Revenues Up 31 Percent

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

What's Popular?

C2i Genomics Acquires Sequencing Lab QNA Dx

Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Fulgent Genetics Q4 Revenues Skyrocket

Sponsorships